The safety and efficacy of bevacizumab in treatment of recurrent low-grade glioma: a systematic review and meta-analysis
1. 系统已在2025-03-03 09:24:42对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: https://link.springer.com/article/10.1007/s00228-024-03695-5
其他信息:
MA Habibi, F Rashidi, H Gharedaghi…
European Journal of …, 2024
Springer
Background Central nervous system (CNS) tumors are among the most common malignancies in various age ranges. Low-grade glioma (LGG) can account for nearly 30% of pediatric CNS malignancies. Progression or recurrence after the first-line treatments is common among these patients. Therefore, more treatments are required. Bevacizumab as an anti-VEGF antibody has come into the spotlight recently and is especially used in relapse or recurrence settings. This review aims to study the safety and efficacy of bevacizumab for …
